GMP LPS: Why a Well-Characterized Inflammatory Challenge Agent Matters in Human Translational Clinical Trials

By John Neville, PhD
List Labs
September 2026

Lipopolysaccharide, or LPS, has long been one of the most important tools for studying innate immune activation. As a Toll-like receptor 4 agonist, LPS can trigger a rapid and measurable 

inflammatory response, making it useful for studying cytokine biology, endotoxin tolerance, immune suppression, pulmonary inflammation, and the pharmacodynamic effects of anti-inflammatory therapies. [1]

But when LPS is used in human clinical research, the requirements change significantly. A research-use reagent is not sufficient. Investigators need a GMP-manufactured inflammatory challenge agent that is characterized, documented, and supplied in a way that supports regulatory review and subject safety. [1]

That is where GMP LPS becomes important. For clinical investigators and drug developers, a well-characterized GMP LPS product can provide a controlled way to induce acute inflammatory responses in human studies, helping bridge the gap between preclinical models and clinical pharmacology. [2-8]

Why LPS Remains Valuable in Human Inflammation Models

Inflammation is central to many areas of disease, including sepsis, respiratory disease, cardiovascular disease, metabolic dysfunction, neuroinflammation, and immune-mediated disorders. Yet studying inflammation in humans can be difficult because natural diseases are heterogeneous. Patients differ in timing, severity, comorbidities, infection source, prior treatments, genetics, and immune status.

Controlled LPS challenge models help address part of that problem. By administering a defined amount of LPS under a clinical protocol, researchers can induce a transient inflammatory response and study immune activation in a more standardized way. [2,4,7]

Depending on the route of administration and study design, LPS challenge models may be used to evaluate:

• Systemic cytokine responses
• Endotoxin tolerance and immune suppression
• Monocyte and myeloid cell function
• Pulmonary or airway inflammation
• Local skin inflammation
• Pharmacodynamic effects of immunomodulatory drugs
• Biomarker changes following acute inflammatory stimulation

These models do not replace disease studies. Instead, they provide an important translational tool. They allow researchers to ask whether a mechanism observed in vitro or in animal models produces measurable effects in humans. [2,5,8]

Clinical-Grade LPS Is Different from Research-Use LPS

LPS is biologically potent. That is exactly why it is useful, but also why clinical use requires careful control. When used in humans, investigators need confidence in the identity, purity, consistency, sterility, documentation, and regulatory support associated with the material. [1]

Clinical research programs must think beyond whether LPS produces an inflammatory response. They need to know whether the product can be used in a controlled way.

Key considerations include:

• Defined bacterial source and LPS type
• Consistent manufacturing and purification
• Removal of unwanted protein and nucleic acid impurities
• Sterile presentation suitable for clinical research
• Lot-specific characterization and documentation
• Regulatory documentation to support IND and EMA review
• Temperature-controlled shipment and handling
• Clear intended use within a clinical protocol

For human studies, these details matter. The goal is not simply to trigger inflammation. The goal is to create a defined, reproducible, and clinically manageable inflammatory challenge that can support meaningful interpretation of study results.

Why E. coli O113 Matters

List Labs GMP LPS is produced from Escherichia coli O113:H10:K-. The O113 designation refers to the O-antigen type, H10 refers to the flagellar antigen type, and K- indicates capsule negative. [1]

This strain type is scientifically important because E. coli O113 has a long history in endotoxin standardization and human inflammatory challenge research. List Labs notes that this type was used for the National Reference Endotoxin and the Second International Standard for Endotoxin. [1]

For clinical research, that history matters. A defined and well-characterized LPS type helps researchers build on prior human challenge work, compare across studies more meaningfully, and support regulatory conversations with a stronger scientific foundation.

What GMP Manufacturing Adds

The value of GMP LPS is not only the LPS itself. It is the control strategy around the product.

List Labs developed a purification method compliant with cGMP guidelines under 21 CFR 211. The process yields a highly purified LPS product that is sterilizable by filtration and free of contaminating protein and nucleic acids. The product is supplied as a sterile lyophilized drug product and is available to clinical researchers working under FDA-submitted INDs. [1]

For researchers, this can reduce several common barriers. Custom manufacturing a GMP LPS product may be expensive and time-consuming, especially because many clinical studies require relatively small quantities. Having GMP LPS available in stock allows researchers to purchase the amount needed rather than fund an entire custom production campaign. [1]

Regulatory support is also important. List Labs has submitted a Drug Master File to FDA, and U.S. customers can request an authorizing cross-reference letter allowing FDA to review relevant product information in support of an IND. For programs in the European Union, when GMP LPS is used as an auxiliary medicinal product or clinical challenge agent, an Auxiliary Medicinal Product Dossier, or AxMPD, can be prepared to support clinical trial submissions. [1,9]

For clinical research teams, that combination of manufacturing control, characterization, availability, and regulatory documentation can help reduce avoidable delays.

How GMP LPS Is Used in Human Studies

Recent clinical studies illustrate the breadth of research questions that can be addressed using GMP LPS as a challenge agent.

In systemic inflammation models, intravenous LPS has been used to induce a controlled inflammatory response in healthy volunteers. These studies have helped researchers examine cytokine release, immune tolerance, monocyte function, myelopoiesis, interferon signaling, and the transition from hyperinflammatory responses to later immune suppression. [2,4,5,7]

GMP LPS has also been used in pharmacodynamic studies of anti-inflammatory therapies. Clinical researchers have used LPS challenge models to evaluate whether investigational agents suppress local or systemic inflammatory responses in humans. For example, oral IRAK4 inhibitors were evaluated using intravenous LPS challenge, while POLB 001, a p38 MAPK inhibitor, was evaluated using both intradermal and intravenous LPS challenges. [6,8]

In pulmonary research, segmental LPS challenge has been used to study localized lung inflammation and the effects of investigational therapies on airway inflammatory responses. In this setting, LPS is instilled into a defined lung segment during bronchoscopy, allowing researchers to evaluate changes in bronchoalveolar lavage, cytokines, immune cell recruitment, imaging-based endpoints, and tissue-specific inflammatory pathways. [3]

In other models, intradermal LPS has been used to generate local inflammatory responses in the skin, allowing investigators to assess erythema, perfusion, blister fluid cytokines, and immune cell migration. This can be especially useful when researchers want to evaluate both local and systemic pharmacodynamic effects in the same clinical program. [8]

Across these examples, the common theme is not that LPS models fully reproduce disease. They do not. Their value is that they create a defined and measurable inflammatory challenge in humans, making them useful for mechanism testing, biomarker development, and early clinical pharmacology. [2-8]

Lessons from Recent Clinical Trials

Several lessons are emerging from studies that use GMP LPS in human inflammatory challenge models.

First, in vivo immune responses cannot always be predicted from ex vivo or in vitro assays. Human LPS challenge studies have shown that cellular responses measured outside the body may not fully reflect systemic cytokine responses or tolerance patterns after LPS administration. This reinforces the importance of human translational models when evaluating immune mechanisms. [2]

Second, LPS challenge can help reveal both acute inflammation and immune tolerance. Some studies use repeated LPS exposure to examine how the immune system responds to an initial inflammatory stimulus and how responsiveness changes after tolerance develops. This is particularly relevant to sepsis research, where patients may experience both hyperinflammation and later immune suppression. [2,4,5,7]

Third, LPS challenge models can support early drug development by providing measurable pharmacodynamic readouts. Investigational therapies targeting inflammatory signaling, cytokine adsorption, bradykinin signaling, p38 MAPK, IRAK4, or innate immune pathways have been evaluated using LPS-induced inflammatory responses. These studies can help determine whether a therapy affects the intended inflammatory pathway in humans. [3,4,6,8]

Fourth, route of administration matters. Intravenous, intradermal, and segmental pulmonary LPS challenge approaches generate different types of data. The appropriate model depends on the biological question, the target tissue, the expected mechanism of action, and the clinical endpoints of interest. [3,6,8]

Finally, product quality and documentation matter because the challenge agent becomes part of the clinical model. If the inflammatory stimulus is not well characterized, consistent, and appropriately documented, it becomes harder to interpret pharmacodynamic results with confidence. [1]

What Researchers Should Consider Before Using GMP LPS

Before incorporating GMP LPS into a clinical study, investigators should align internally across clinical, regulatory, safety, pharmacy, and translational science teams.

Important planning questions include:

• What route of administration best fits the research question?
• Is the study intended to evaluate systemic, local, or tissue-specific inflammation?
• What dose and timing are supported by prior literature and protocol objectives?
• What clinical monitoring is required for subject safety?
• Which cytokines, cell populations, imaging endpoints, or biomarkers will be measured?
• How will the study distinguish target engagement from broader inflammatory effects?
• What regulatory documentation is needed for IND or clinical trial review?
• How will the product be stored, prepared, handled, and administered?

These questions should be addressed early because LPS challenge studies require careful coordination. The challenge agent, clinical protocol, biomarker strategy, and safety plan must work together.

Where List Labs Fits

List Labs GMP LPS, Lipopolysaccharide List HPT from E. coli Type O113, was developed to support clinical researchers using LPS as an inflammatory challenge agent under appropriate regulatory oversight. [1]

List Labs GMP LPS, Catalog #9433A, is supplied as sterile lyophilized material. The product is manufactured using a cGMP-compliant purification approach, supported by lot-specific documentation, and associated with a Drug Master File accepted by FDA. For U.S. clinical researchers, an authorizing cross-reference letter can be requested to support IND review. For programs in the European Union, when GMP LPS is used as an auxiliary medicinal product or clinical challenge agent, an Auxiliary Medicinal Product Dossier, or AxMPD, can be prepared to support clinical trial submissions. [1,9]

For investigators studying inflammation, immune tolerance, pulmonary responses, pharmacodynamic effects of immunomodulatory therapies, or cancer immunotherapty, access to a well-characterized GMP LPS product can help reduce the need for custom manufacturing and support a more efficient path into clinical research.

The broader lesson is that clinical challenge agents should be treated with the same discipline as other clinical materials. When the goal is to generate interpretable human immune-response data, the quality and documentation of the inflammatory stimulus matter.

FAQ: GMP LPS in Clinical Trials

What is GMP LPS?
GMP LPS is lipopolysaccharide manufactured and controlled under GMP-compliant conditions for use in clinical trial protocols. It is intended to serve as a controlled inflammatory challenge or immunomodulatory agent in human studies conducted under appropriate regulatory oversight. [1]
Why is LPS used in human challenge studies?
LPS activates innate immune responses through TLR4 signaling. In controlled clinical settings, it can induce measurable inflammatory responses, including cytokine release, changes in immune cell function, and local or systemic inflammatory endpoints. [1-8]
Is GMP LPS the same as research-use LPS?
No. Research-use LPS is intended for laboratory use only. GMP LPS is manufactured, characterized, documented, and supplied in a manner intended to support clinical research use under an IND or similar regulatory framework. [1]
What types of studies use GMP LPS?
GMP LPS has been used in systemic inflammation studies, endotoxin tolerance models, pulmonary challenge studies, intradermal inflammation models, pharmacodynamic studies of investigational anti-inflammatory therapies, and cancer immunotherapies. [2-8]
Why is regulatory documentation important?
Because GMP LPS is used as a clinical challenge agent, regulators need information about its identity, manufacturing, controls, purity, sterility, characterization, and handling. Documentation such as a Drug Master File cross-reference or AxMPD can help support regulatory review, depending on the geography and clinical trial framework. [1,9]

Looking Ahead

Human inflammatory challenge models remain important tools for translational research. They provide a controlled way to study innate immune activation, evaluate pharmacodynamic effects, and explore inflammatory pathways in humans before or alongside patient studies. [2-8]

As immunomodulatory therapies become more targeted, the need for well-characterized clinical challenge agents will continue to grow. Whether the goal is to study systemic inflammation, immune tolerance, pulmonary inflammation, or local inflammatory responses, the quality of the LPS product matters.

For clinical researchers, GMP LPS is more than an endotoxin reagent. It is a controlled translational tool that can help turn complex immune biology into measurable human data.

References

[1] List Biological Laboratories. GMP LPS: Lipopolysaccharide List HPT from Escherichia coli Type O113. List Labs GMP Products page. Link

[2] Jansen A, Bruse N, Waalders N, Gerretsen J, Rijbroek D, Pickkers P, Kox M. Ex vivo and in vitro Monocyte Responses Do Not Reflect in vivo Immune Responses and Tolerance. Journal of Innate Immunity. 2023;15(1):174-187. Link

[3] Gress F, Vogel-Claussen J, Badorrek P, et al. The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers. Pulmonary Pharmacology & Therapeutics. 2023;82:102246. doi:10.1016/j.pupt.2023.102246. Link

[4] Jansen A, Waalders NJB, van Lier DPT, et al. CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo. Critical Care. 2023;27:117. doi:10.1186/s13054-023-04391-z. Link

[5] Schrijver DP, Roring RJ, Deckers J, et al. Resolving sepsis-induced immunoparalysis via trained immunity by targeting interleukin-4 to myeloid cells. Nature Biomedical Engineering. 2023;7:1097-1112. doi:10.1038/s41551-023-01050-0. Link

[6] Jodl J, Ten Voorde W, Klein SK, et al. The oral IRAK4 inhibitors zabedosertib and BAY1830839 suppress local and systemic immune responses in a randomized trial in healthy male volunteers. Clinical and Translational Science. 2024;17(3):e13771. doi:10.1111/cts.13771. Link

[7] Keramati F, Leijte GP, Bruse N, et al. Systemic inflammation impairs myelopoiesis and interferon type I responses in humans. Nature Immunology. 2025;26:737-747. doi:10.1038/s41590-025-02136-4. Link

[8] de Bruin DT, Jansen MAA, Pereira DR, et al. POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following in vivo LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study. Frontiers in Immunology. 2026;16. doi:10.3389/fimmu.2025.1684307. Link

[9] Central Committee on Research Involving Human Subjects. Auxiliary Medicinal Product Dossier (AxMPD). Guidance page describing AxMPs, including challenge agents, and AxMPD requirements. Link